# A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Source: https://onco.cc/trials/nct05710848/  
OnCo record `nct05710848` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of STM-416 in bladder & urothelial cancer, run by SURGE Therapeutics, now recruiting.

## Summary

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer is a phase 1/2 interventional study registered as NCT05710848 by SURGE Therapeutics, with 75 participants planned, started 2023-07-11 and due to reach its primary completion in 2026-05. Interventions recorded: STM-416.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05710848
- Phase: 1/2
- Setting: A Phase 1/2a Study of STM-416 Administered Intraoperatively to Patients Undergoing Transurethral Resection of Bladder Tumor (TURBT) for Recurrent High-Grade Papillary Bladder Cancer
- Sponsor: SURGE Therapeutics
- Enrolled: 75

## Sources

- ClinicalTrials.gov NCT05710848: https://clinicaltrials.gov/study/NCT05710848

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)

---
JSON: https://onco.cc/api/v1/entities/nct05710848.json